MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Arcutis Biotherapeutics Inc

Suletud

SektorTervishoid

14.7 1.8

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.12

Max

14.87

Põhinäitajad

By Trading Economics

Sissetulek

31M

-11M

Müük

27M

71M

Aktsiakasum

-0.09

Kasumimarginaal

-15.118

Töötajad

342

EBITDA

29M

-4.5M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+31.49% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

155M

1.6B

Eelmine avamishind

12.9

Eelmine sulgemishind

14.7

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Intel, AppFolio

24. apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. apr 2025, 23:37 UTC

Peamised uudised

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. apr 2025, 23:36 UTC

Peamised uudised

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. apr 2025, 23:13 UTC

Peamised uudised
Tulu

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. apr 2025, 23:09 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. apr 2025, 22:51 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 22:48 UTC

Peamised uudised

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. apr 2025, 22:38 UTC

Market Talk
Tulu

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. apr 2025, 22:24 UTC

Market Talk
Tulu

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. apr 2025, 22:23 UTC

Tulu

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. apr 2025, 22:11 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

24. apr 2025, 22:11 UTC

Market Talk
Tulu

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. apr 2025, 22:09 UTC

Peamised uudised
Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. apr 2025, 22:00 UTC

Market Talk
Tulu

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. apr 2025, 21:39 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. apr 2025, 21:24 UTC

Peamised uudised
Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 21:24 UTC

Peamised uudised
Tulu

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. apr 2025, 21:23 UTC

Peamised uudised
Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. apr 2025, 21:04 UTC

Tulu

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. apr 2025, 21:02 UTC

Tulu

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

31.49% tõus

12 kuu keskmine prognoos

Keskmine 19 USD  31.49%

Kõrge 21 USD

Madal 15 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

14.01 / 15.02Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.